On August 9, 2023, DECIPHERA PHARMACEUTICALS ($NASDAQ:DCPH) released their earnings results for the second quarter of the 2023 fiscal year (ending June 30, 2023). Total revenue was USD 38.3 million, a 17.9% rise from the same quarter in the prior year. Net income for the quarter amounted to USD -48.6 million, lower than the -43.1 million recorded in the year before.
Furthermore, the company also reported their highest quarterly revenue in their history, helping to further bolster the stock value. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Deciphera Pharmaceuticals. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Deciphera Pharmaceuticals. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Deciphera Pharmaceuticals. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Deciphera Pharmaceuticals are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
We at GoodWhale recently conducted an analysis of DECIPHERA PHARMACEUTICALS‘ wellbeing. Our star chart shows that DECIPHERA PHARMACEUTICALS is classified as a ‘cheetah’, which indicates high revenue or earnings growth with lower profitability than average. This could be attractive to investors who are comfortable with taking on a higher risk in exchange for higher potential rewards. From our analysis we can see that DECIPHERA PHARMACEUTICALS is strong in asset growth but weak in dividend and profitability. Its health score of 5/10 with regard to cashflows and debt suggests that it is likely to sustain future operations in times of crisis. This could make the company attractive to investors looking for stability in a high growth market. More…
Risk Rating Analysis
Star Chart Analysis
The pharmaceutical industry is a highly competitive marketplace.
However, the company faces stiff competition from a number of other companies, including Cardiol Therapeutics Inc, Redhill Biopharma Ltd, and SCYNEXIS Inc. Each of these companies has a strong presence in the industry and is well-positioned to compete for market share.
– Cardiol Therapeutics Inc ($TSX:CRDL)
Cardiol Therapeutics Inc is a Canadian biopharmaceutical company focused on the research and development of therapies for heart failure. The company has a market cap of 43.98M as of 2022 and a Return on Equity of -40.02%. Cardiol’s lead product candidate is CD101, an investigational therapy for the treatment of heart failure. CD101 is currently in a Phase II clinical trial.
– Redhill Biopharma Ltd ($NASDAQ:RDHL)
Redhill Biopharma Ltd is a publicly traded biopharmaceutical company. The company’s focus is on the development and commercialization of therapies for gastrointestinal diseases and cancer. The company’s lead product, TALICIA, is approved in the United States for the treatment of Helicobacter pylori infection. The company’s second product, RHB-105, is being developed for the treatment of H. pylori infection and gastric cancer. The company has a market cap of $39.57M and a ROE of -2625.79%.
SCYNEXIS Inc is a biopharmaceutical company that focuses on the development and commercialization of anti-infective therapies. The company’s market cap is $73.14 million and its ROE is -72.72%. SCYNEXIS Inc’s main product is its lead drug, ibrexafungerp, which is in clinical development for the treatment of fungal infections.
Deciphera Pharmaceuticals reported strong financial results for the second quarter of fiscal year 2023 (ending June 30, 2023) on August 9, 2023. Despite this decrease in net income, stock price moved up on the news, indicating a positive outlook among investors. With a solid revenue increase and good showing in the markets, Deciphera Pharmaceuticals appears to be a promising investment opportunity for investors willing to take on some risk.